Clinical Trials Arena June 6, 2024
The approval is a significant development in the field and will encourage the use of mRNA technology across other disciplines.
Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has received US Food and Drug Administration (FDA) approval for use in adults ages 60 years and older, the first time that an mRNA vaccine has been approved for a disease other than Covid-19. This approval represents a significant development in the field and is likely to encourage the use of mRNA technology across other disciplines.
The approval was granted under a breakthrough therapy designation and supported by positive results from the global Phase III ConquerRSV trial. The vaccine demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease (LRTD) in patients...
Today's Sponsors
Today's Sponsor